General Equipments and Health Products Agency

Paris, France

General Equipments and Health Products Agency

Paris, France
SEARCH FILTERS
Time filter
Source Type

Rotival R.,General Equipments and Health Products Agency | Bernard M.,General Equipments and Health Products Agency | Henriet T.,General Equipments and Health Products Agency | Fourgeaud M.,General Equipments and Health Products Agency | And 6 more authors.
Journal of Pharmaceutical and Biomedical Analysis | Year: 2014

The FEE cyclic hexapeptide (cFEE) is an investigational new drug added to the insemination medium in order to improve the in vitro fertilization rate. The pharmacological activity of small peptides is highly dependent on the conservation of the amino acid sequence and of the structural conformation of the active site. To enhance the scientific knowledge required for the clinical use of cFEE, a comprehensive determination of its chemical stability in solution was realized in accelerated conditions. Degradation products have been detected and identified by liquid chromatography/Qtrap® mass spectrometry. The main degradation products highlighted during the product shelf life were produced by hydrolysis and only certain sites were involved. In most cases, the cyclic conformation was lost and regarding the major degradation pathway, the sequence representing the active site was affected. © 2013 Elsevier B.V.


PubMed | University of Paris Descartes and General Equipments and Health Products Agency
Type: | Journal: Journal of pharmaceutical and biomedical analysis | Year: 2013

The FEE cyclic hexapeptide (cFEE) is an investigational new drug added to the insemination medium in order to improve the in vitro fertilization rate. The pharmacological activity of small peptides is highly dependent on the conservation of the amino acid sequence and of the structural conformation of the active site. To enhance the scientific knowledge required for the clinical use of cFEE, a comprehensive determination of its chemical stability in solution was realized in accelerated conditions. Degradation products have been detected and identified by liquid chromatography/Qtrap() mass spectrometry. The main degradation products highlighted during the product shelf life were produced by hydrolysis and only certain sites were involved. In most cases, the cyclic conformation was lost and regarding the major degradation pathway, the sequence representing the active site was affected.

Loading General Equipments and Health Products Agency collaborators
Loading General Equipments and Health Products Agency collaborators